Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, January 10, 2018

Telemedicine decreases time to alteplase administration for stroke

What a pile of shit, totally wrong test for primary measure. It should have been 100% recovery after administration. This is why stroke never gets anywhere, we have no one that is even trying to actually solve the correct problem in stroke. You're screwed along with your children and grandchildren until we get stroke survivors running the stroke associations. 
https://www.healio.com/cardiology/stroke/news/online/%7B845cb641-2220-4017-9fa6-da6fe8d7c89e%7D/telemedicine-decreases-time-to-alteplase-administration-for-stroke?utm_source=selligent&utm_medium=email&utm_campaign=cardiology%20news&m_bt=592835816269
A novel telemedicine program increased alteplase administration rates and shortened door-to-needle times without an increase in adverse outcomes, according to a study published in Stroke.
“When a stroke happens, minutes matter,” Mai Nguyen-Huynh, MD, MAS, vascular neurologist and research scientist in the division of research at Kaiser Permanente in Oakland, California, said in a press release. “Faster treatment with intravenous [alteplase], which dissolves the stroke-causing clot and restores blood flow to the brain, is strongly associated with better functional outcomes for stroke patients.”
Researchers analyzed data from 310 patients (mean age, 71 years; 50% women) who received alteplase (Activase, Genentech) before the telemedicine program was implemented and 557 patients (mean age, 74 years; 53% women) who received it after the program was initiated in 21 Kaiser Permanente Northern California hospitals.
The telemedicine program included ambulance prenotification, neurological evaluation, medical history review from electronic medical records, notification of potential transfer for endovascular stroke treatment, alteplase administration in the CT suite and rapid transport to the suite. A teleneurologist was on-call to examine and monitor the patient.
The primary outcome was the door-to-needle time for the administration of alteplase. Secondary outcomes were symptomatic intracranial hemorrhage, rate of alteplase administrations per month and disposition at discharge.
Alteplase administrations increased from 34 per month before implementation to 62 per month once the program was in place (P < .001). Door-to-needle times decreased from 52 minutes to 34 minutes (P < .001).
Alteplase administration times of less than 60 minutes occurred in 87.1% of patients during the program vs. 61% before it was implemented (P < .001). Patients who were treated within 30 minutes increased from 4.2% before the program was initiated to 40.8% after the program started (P < .001).
The rate of symptomatic intracranial hemorrhage was similar before (2.2%) and after (3.8%) the program was in place (P = .29).
“Future studies are needed to better evaluate the long-term sustainability of the intervention and its effect on clinical outcomes, including mortality and long-term disability,” Nguyen-Huynh and colleagues wrote. – by Darlene Dobkowski
Disclosures: The study was funded by the Permanente Medical Group. Nguyen-Huynh reports she received funding from the Permanente Medical Group.

No comments:

Post a Comment